Helen Reeves Consultant Hepatologist Newcastle

Helen Reeves Consultant Hepatologist Newcastle

Helen Reeves Consultant Hepatologist Newcastle is a renowned expert in liver disease and cancer research. As Professor of Liver Cancer at Newcastle University’s Centre for Cancer, she brings decades of clinical and academic excellence to her role. At the Freeman Hospital in Newcastle, Helen serves as a consultant physician hepatologist, offering world-class care to patients across Northern England.

Her special interests include hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD), chemotherapy-induced liver injury, pancreatic cancer, and colorectal liver metastases. Through a dynamic and evolving career, Helen has remained dedicated to advancing treatments for liver-related diseases and cancer.

Helen Reeves Consultant Hepatologist Newcastle: Education and Early Career

Helen graduated from Nottingham Medical School in 1990. Shortly after, she relocated to Newcastle to work under the mentorship of Professor Oliver James. Her commitment to research took her across the Atlantic to New York, where she collaborated with Professor Scott Friedman at Mount Sinai Medical School. There, she explored the molecular pathogenesis of cancers in a post-doctoral role.

With a PhD in liver fibrosis cell signaling, she has built a strong foundation in both clinical and scientific research. Her dedication has consistently bridged the gap between laboratory findings and patient care.

Clinical and Leadership Roles in Newcastle

Currently, Helen Reeves Consultant Hepatologist Newcastle leads clinical care for hepatocellular carcinoma across Northern England. She plays a vital role in shaping regional treatment protocols and patient outcomes.

Her leadership extends to major scientific communities. She has served on the scientific committee for the British Association for Cancer Research and the European Association for the Study of the Liver (EASL). Additionally, she actively contributes to the EASL Education Committee and the HCC-UK Committee, helping shape the future of liver cancer education and care.

Research and Scientific Impact

Helen’s research primarily targets primary liver cancer in NAFLD patients. She seeks to develop biomarkers with real-world clinical applications. As a principal investigator, she holds a Cancer Research UK (CRUK) program grant investigating neutrophils’ roles in liver cancer.

She also leads the HUNTER initiative—Hepatocellular Carcinoma Expediter Network—a collaborative project funded by CRUK, FC AECC, and AIRC. Through this, Helen connects scientists and clinicians across Europe to fast-track liver cancer breakthroughs.

Commitment to Education and Mentorship

Helen maintains a strong focus on nurturing the next generation of medical researchers. She actively promotes training programs for young investigators and clinical scientists. By mentoring emerging professionals, she ensures the continued growth of liver disease research and patient care innovation.